Findings

What do systematic reviews say?

7 questions · 7 findings · 2 reviews · Skin

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 4 · 57.1%Moderate 3 · 42.9%High 0 · 0%

Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus

Oral ciclosporin showed no clear difference in adverse events: severe compared with oral azathioprine (low certainty).

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
RR 0.89 [0.48, 1.65]
1 study · 89 participants
Low

Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus

Oral methotrexate showed no clear difference in adverse events: severe compared with oral chloroquine (low certainty).

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
RR 1.73 [0.27, 11.07]
1 study · 41 participants
Low

Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus

Oral chloroquine showed no clear difference in adverse events: severe compared with placebo (low certainty).

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
RR 0.33 [0.01, 7.45]
1 study · 24 participants
Low

Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus

Oral methotrexate showed no clear difference in adverse events: severe compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
RR 12.05 [0.69, 211.36]
1 study · 86 participants
Moderate

Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus

Oral hydroxychloroquine showed no clear difference in adverse events: severe compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
RR 3.9 [0.19, 78.46]
1 study · 71 participants
Moderate

Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus

Oral dehydroepiandrosterone showed no clear difference in adverse events: severe compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
RR 0.09 [0.01, 1.66]
1 study · 381 participants
Moderate

Adverse events: severe complications at day 21 · bullous pemphigoid

Clobetasol propionate cream may leads to lower adverse events: severe complications at day 21 compared with oral prednisone (low certainty).

1 finding from 1 review

Interventions for bullous pemphigoid 2023 · Cochrane Headline outcomes only
RR 0.65 [0.5, 0.86]
1 study · 341 participants
Low